Bacillus Calmette-Guerin (BCG),4 an attenuated strain of Mycobacterium bovis, was developed as a vaccine against human tuberculosis by Calmette and Guerin at the Pasteur Institute in 1908. BCG has recently regained the spotlight in completely different roles, that of an immunological adjuvant and "'antitumor" agent. Investigations with this agent in the immunotherapy of cancer have met with var...

Ecological studies are one of the most common study designs used to establish association between certain factors and disease development. However, they have limitations mainly on how measure variables, so their results must be verified in with greater validity. Therefore, that links possible relationship higher mortality from COVID-19 non-vaccination by bacillus Calmette-Guerin (BCG) was recen...

The Calmette--Guerin Bacillus (BCG), an attenuated live strain of Mycobacterium bovis was originally developed by Albert Leon Charles Calmette and Camile Guerin in 1925 as a vaccine for tuberculosis. At the present, BCG is widely used as a complementary therapy for superficial bladder neoplasms. This treatment is considered to be safe and well tolerated although local and distal complications m...

There is clear evidence that BCG protects against leprosy, but cross-immunity with environmental mycobacteria can interfere with vaccination protection. Some have cast doubts whether BCG vaccination can offer a significant impact against leprosy in the Brazilian Amazon, which is an endemic area for leprosy and with a high prevalence of environmental mycobacteria. This study was designed to esti...

bacillus calmette guerin (bcg) developed by albert calmette and camille guerin in france between 1908 and 1921 contained a live attenuated strain of mycobacterium bovis and was administered worldwide to prevent tuberculosis. bcg vaccination is also administered at birth to all the newborns in iran. disseminated bcg infection after bcg vaccination is rare. here in, we report 2 new cases of disse...

PURPOSE We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. MATERIALS AND METHODS We retrospectively reviewed the charts of 697 patients treated with bacillus Calmette-Guerin instillations at our institution from 1991 to 2004. In 24 patients (3.5%) an underlying comorbidity directly affecting the immune ...

Disseminated mycobacterial infection after bacillus Calmette-Guerin (BCG) vaccination is a very rare disorder, occurring mostly in patients with immunologic deficiency. We report a case of disseminated BCG infection in a 16-month-old girl with severe combined immunodeficiency. Plain radiographs showed multiple osteolytic lesions in the femora, tibiae, humerus, and phalanges. Abdominal sonograph...

Submit Manuscript | http://medcraveonline.com Abbreviations: NDV: Newcastle Disease Virus; APMV-1: Avian Paramyxovirus Type I; IFN: Interferon; CTLA-4: Cytotoxic T Lymphocyte Associated Antigen-4; RCC: Renal Cell Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; IL-2: Interleukin-2; DTH: Delayed Type Hypersensitivity; Gy: Gray; BCG: Bacillus Calmette-Guerin; HN: Hemagglutinin-Neuraminida...

Rare cases of tuberculous urinary tract or genital infection caused by intravesical Intravesical Bacillus Calmette-Guerin (BCG) instillation therapy have been reported. We encountered a patient with tuberculous granuloma in the scrotal skin after intravesical BCG therapy for bladder cancer. There was evidence of infection in the scrotal skin, but not in the epididymis. To the best of our knowle...